Product Description
Mechanisms of Action: Calcium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Bangladesh | Bosnia | Brazil | Bulgaria | Chile | China | Colombia | Croatia | Czech | Denmark | Dominican Republic | Egypt | Estonia | Germany | Greece | Hong Kong | Hungary | India | Italy | Korea | Latvia | Lithuania | Malta | Mexico | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Singapore | Slovakia | Slovenia | Spain | Sweden | Taiwan | Turkey | United Kingdom | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Hypertension|Type 2 Diabetes
Phase 3: Hypertension
Phase 2: Angina, Stable|Angina Pectoris
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20191645 | N/A |
Completed |
Healthy Volunteers |
2020-04-13 |
|
| ELDER | P4 |
Completed |
Hypertension |
2009-07-01 |
|
| NCT00338338 | P4 |
Completed |
Hypertension |
2007-09-14 |
|
| LAC103842 | P4 |
Completed |
Type 2 Diabetes|Hypertension |
2006-05-01 |